The abstract is read at the publisher; the summary is JClub's.
In the ADORE randomized trial cohort, FADS Indel I-allele carriers receiving 1,000 mg/day DHA had lower early preterm birth (EPB) than D/D carriers (1.1% vs 4.3%).
- Why it matters: EPB (<34 weeks) contributes substantially to newborn morbidity and mortality, and preventive options are limited; genotype-linked DHA response could enable precision dosing.
- What they did: A post hoc secondary analysis genotyped rs66698963 FADS Indel in participants at 12–20 weeks from three US centers, comparing 200 vs 1,000 mg/day DHA using treatment-specific Bayesian binomial models.
- The result: Genotype-by-dose effects credibly differed for EPB and prolonged gestation (interaction PP=0.99 and 0.98), suggesting FADS Indel may predict direction of response to high-dose DHA.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.